AMAG Pharmaceuticals — Q4 2015 Earnings Presentation
30 slides from AMAG Pharmaceuticals's earnings presentation, Feb 17, 2016
Slide 1: Forward-looking statements
This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other federal securities laws. Any statements contained herein which do not describe historical facts, including among others, statements regarding expected 2015 finan
Slide 2: 4Q 2015 Earnings Call Agenda
4Q 2015 Earnings Call Agenda Transformational Growth 1 2 3 4 2016 Key Priorities and Closing Remarks 5 Q&A 5 Commercial Performance and Developments 4Q 2015 Results and Financial Update
Slide 3: 2015 In Review
2015 In Review Solid financial performance1 Makena sales +52% from 2014 pro forma revenue Adjusted EBITDA increased to $213.4 MM, compared with $14.3 MM in 2014 Non-GAAP diluted EPS increased to $4.43, compared with $0.30 in 2014 Expanded portfolio and advanced pipeline development programs Acquired
Slide 4: 4Q/FY 2015 Financial Results
Copyright © 2015 AMAG Pharmaceuticals. All Rights Reserved. 4Q/FY 2015 Financial Results
Slide 5: 4Q 2015 – Finished the Year Strong
4Q 2015 – Finished the Year Strong Non-GAAP Revenue1 ($ MM) Non-GAAP Adjusted EBITDA1 ($ MM) Non-GAAP Diluted EPS1 ($/share) Grew non-GAAP revenue 137% and adjusted EBITDA 322% Exited 2015 with $466.3 MM in cash & investments and 34.7 MM basic shares outstanding Total net leverage ratio ~2.4x annual
Slide 6: Full Year 2015 Financial Summary GAAP to Non-GAAP Comparison
Full Year 2015 Financial Summary GAAP to NON-GAAP Comparison1 1 Unaudited. See slides 23-25 for a reconciliations of GAAP to non-GAAP financial information. 2 See slide 27 for share reconciliation. ($ in millions, except per share data) 2015 (GAAP) Adjustments 2015 (Non-GAAP) Total revenues $418.3 $
Slide 7: Full Year 2015 Financial Summary GAAP to Non-GAAP Comparison
GAAP TO NON-GAAP COMPARISON! Gam ag Full Year 2015 Financial Summary 2015 $ in millions, except per share data ( pt p ) (GAAP) Adjustments 2015 (Non-GAAP) Total revenues $418.3 $20.8 Cost of revenue 88.5 (66.1) Gross margin $329.8 $45.2 Operating expenses 218.6 (57.0) Operating income / Adjusted EBI
Slide 8: Makena Recent Accomplishments and Future Growth Drivers
Recent Accomplishments and Future Growth Drivers: Increased 4Q15 market share to 35%, up from 24% in 4Q14 Continue to pull through recent formulary wins Maternal health sales force increased to 104 reps from 76 reps (+37%) ~60% of Makena patients are processed through Makena Care Connection and/or f
Slide 9: Executing on Makena Next Generation Development Programs
Executing on Makena Next Generation Development Programs Makena longer-acting formulation Pre Feb 2018 Post Feb 2018 Preservative free More convenient for HCPs More cost effective for insurers In vivo feasibility established Less frequent injections More convenient for patient and HCP Provides oppor
Slide 10: Significant Decrease in Needle Size
Significant Decrease in Needle Size 11 Makena IM1 Injection vs. subcutaneous injection Makena currently injected with large 21 gauge needle into the muscle Advantage of auto-injector is that it allows for subcutaneous administration of Makena Specifically designed for administration of viscous mater
Slide 11: Favorable Physician Response to Makena Next Generation Products
Favorable Physician Response to Makena Next Generation Products Physician’s Therapy Preferences Makena is the therapy of choice for at-risk women Respondents state that Makena is administered ~70% in-office, while ~30% administered at-home by nurse/care-giver Makena single-dose launch offers an oppo
Slide 12: CBR: Unlocking the Potential Value of Newborn Stem Cells
CBR: Unlocking the Potential Value of Newborn Stem Cells Recurring revenue with upside potential: Revenue model: One-time, upfront collection and processing fee On-going annual storage fees Strong brand recognition and customer loyalty 633,000+ units cumulatively stored <1% annual attrition rate Fut
Slide 13: Hematology / Oncology and Hospital
Hematology / Oncology and Hospital
Slide 14: Feraheme Key Growth Drivers
Key Growth Drivers Feraheme is indicated for the treatment of iron deficiency anemia (IDA) in adults with chronic kidney disease (CKD) Six Orange Book listed patents, five of which expire in 2020 and one which expires in 20231 Recent Accomplishments and Future Growth Drivers Returned to growth after
Slide 15: Feraheme Growth Opportunities
Growth Opportunities 1 If regulatory approval is received for broad IDA indication. 2 Global Intravenous (I.V.) Iron Drugs Market Report: 2015 Edition. Initiating head-to-head Phase 3 clinical trial in 1Q16 to evaluate the safety of Feraheme compared to Injectafer®, with potential approval for broad
Slide 16: Feraheme Growth Opportunities
: Geamag Feraheme Growth Opportunities EXPAND LABEL AND GROW IV IRON MARKET Initiating head-to-head Phase 3 clinical trial in 1Q16 to evaluate the safety of Feraheme compared to Injectafer®, with potential approval for broad IDA indication in 2018.1 4.5 MM patients diagnosed with IDA, many placed on
Slide 17: 2016 Financial Guidance
2016 Financial Guidance ($ MM) 2016 Guidance1 % Increase over 2015 (midpoint of guidance) Makena sales $310 - $340 +29% Feraheme and MuGard sales $95 - $105 +11% Cord Blood Registry revenue $115 - $1253 +1%2 Total non-GAAP product revenue1 $520 - $570 +42% Non-GAAP adjusted EBITDA1 $255 - $285 +27%
Slide 18: Leverage Commercial Expertise with Acquisitions
Leverage Commercial Expertise with the Acquisition of Products/Companies that Accelerate Future Growth Strong Financial profile, management team & corporate infrastructure FUTURE PRODUCT Maternal Health Hematology/Oncology, Nephrology & Hospital Consumer marketing expertise FUTURE PRODUCT CBR Commer
Slide 19: 2016 Key Priorities
2016 Key Priorities Financial and Commercial Drive significant net product sales growth +40% Commercialize single-dose, preservative-free formulation of Makena in 2Q16 Increase non-GAAP adjusted EBITDA to >$255 MM Initiate share repurchase program Product Development Conduct Makena bioequivalence st
Slide 20: AMAG Pharmaceuticals 4Q 2015 Financial Results
AMAG Pharmaceuticals 4Q 2015 Financial Results February 17, 2016
Slide 21: Appendix
AMAG Pharmaceuticals Appendix 4Q 2015 Financial Results February 17, 2016
Slide 22: GAAP to Non-GAAP Financials for the Three Months Ended December 31, 2015
GAAP to Non-GAAP Financials for the Three Months Ended December 31, 2015 Three Months Ended Three Months Ended December 31, 2015 December 31, 2014 GAAP Adjustments Non - GAAP GAAP Adjustments Non - GAAP Revenues: Makena $ 67,356 $ — $ 67,356 $ 2 2,512 $ — $ 22,512 Feraheme/MuGard 23,476 — 23,476 24,
Slide 23: GAAP to Non-GAAP Financials for the Year Ended December 31, 2015
GAAP to Non-GAAP Financials for the Year Ended December 31, 2015 Twelve Months Ended Twelve Months Ended December 31, 2015 December 31, 2014 GAAP Adjustments Non - GAAP GAAP Adjustments Non - GAAP Revenues: Makena $ 251,615 $ — $ 251,615 $ 22,513 $ — $ 22,513 Feraheme/MuGard 90,201 — 90,201 87,485 —
Slide 24: GAAP to Non-GAAP Footnotes
GAAP to non-GAAP Financials for the Three Months and Full Year Ended December 31, 2015 7,17 Adding back period write-down of deferred revenue from purchase accounting. 8,18 Eliminate non-cash revenue related to recognition of previously deferred revenue on Takeda agreement. 9,19 Eliminate the follow
Slide 25: 2016 Financial Guidance Reconciliation
2016 Financial Guidance Reconciliation ($ MM) 2016 Guidance GAAP Net income $11 - $41 CBR deferred revenue purchase accounting adjustments $17 Depreciation & amortization $90 Interest expense, net $72 Provision for income taxes $20 EBITDA $210 - $240 Non-cash inventory step-up $5 Stock-based compens
Slide 26: Share Reconciliation
Share Reconciliation 1 Convertible notes would be ant-dilutive in this period utilizing the “if-converted” method, which adjusts net income for the after-tax interest expense applicable to the Convertible notes. 2 Reflects the impact of the non-GAAP benefit of the bond hedge and warrants. 3 Reflects
Slide 27: Capitalization
($ MM) 4Q15 Cash and cash equivalents $466 Convertible senior notes (2.5%) $200 Term loan facility (4.75%) 346 2023 senior notes (7.875%) 500 Total debt $1,046 Capitalization As of December 31, 2015 ($ MM) 12/31/15 Shares outstanding (millions) 34.7 Net operating loss balance1 $503 1 A portion of th
Slide 28: CBR Non-GAAP Revenue Adjustment
CBR Non-GAAP Revenue Adjustment Purchase accounting future impact Deferred revenue balance on August 17, 2015 Addback to calculate non-GAAP revenue to be reported in future periods ($ MM) Purchase accounting rules require write-down of closing date deferred revenue on balance sheet at acquisition da
Slide 29: AMAG Pharmaceuticals 4Q 2015 Financial Results
AMAG Pharmaceuticals 4Q 2015 Financial Results February 17, 2016
Slide 30: AMAG Pharmaceuticals 4Q 2015 Financial Results
AIVIAG jarmaceuticals 402015 Financial /Results laryil/7 201 ‘A SPECIALTY PHARMACEUTICAL COMPANY DEDICATED TO BRINGING TO MARKET THERAPIES THAT IMPROVE PATIENTS’ LIVES